综合征性遗传性主动脉病患者TEVAR的多中心结局
基于VQI-Medicare链接数据,比较合并与不合并综合征性遗传性主动脉病(SGA)的降胸主动脉TEVAR患者,SGA组188例、非SGA组7688例。校正混杂后,两组30天死亡、卒中、脊髓缺血等术后结局及3年生存、再干预、主动脉破裂风险均无显著差异。
要点
- SGA患者TEVAR术后30天死亡及卒中、脊髓缺血等并发症风险与非SGA患者相似。
- SGA患者3年总体死亡、再干预及主动脉破裂的校正风险与非SGA患者无显著差异。
- SGA患者TEVAR术后中期结局与非SGA相当,但需进一步研究确认。
核心结论
- 合并SGA的患者接受TEVAR后,术后及中期结局与不合并SGA的患者相似。
研究设计与样本
- 基于血管外科学会血管质量倡议-医疗保险链接数据的多中心回顾性队列研究,最终分析纳入7876例因降胸主动脉瘤或夹层行TEVAR的患者,其中SGA患者188例、非SGA患者7688例。
主要发现
- SGA组患者整体更年轻(70.7 vs. 74.2岁,P < 0.01),其他基线人口学特征分布相似。
- 校正潜在混杂因素后,SGA组与非SGA组30天死亡、术后卒中、脊髓缺血、心肌梗死、充血性心力衰竭及呼吸系统并发症的比值无显著差异。
- 随访第一年内两组总体死亡率和再干预率无显著差异。
- 两组3年生存率无显著差异(73.7% vs. 63.1%,log-rank P = 0.11)。
- 校正混杂后,Cox模型显示两组3年总体死亡(aHR: 0.76,95%CI: 0.51-1.12,P = 0.16)、再干预(aHR: 1.09,95%CI: 0.78-1.53,P = 0.61)和主动脉破裂(aHR: 1.09,95%CI: 0.45-2.65,P = 0.85)风险均无显著差异。
临床怎么用
- 对于合并SGA的降胸主动脉瘤或夹层患者,TEVAR术后及中期结局与非SGA患者相似,可作为治疗选择之一。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thoracic aortic aneurysms and dissection in individuals with syndromic genetic aortopathy (SGA) due to Marfan syndrome, Loeys-Dietz syndrome, and vascular Ehlers-Danlos syndrome are especially challenging. This is due to the impaired aortic architecture secondary to the genetic variants. Previous studies have analyzed the outcomes after open surgery in this population. However, there is little information on their outcomes after thoracic endovascular aortic repair (TEVAR). Recent studies have demonstrated high rates of subsequent secondary interventions in these patients treated with TEVAR due to retrograde type A aortic dissection and endoleaks. These diseases are not limited to the descending thoracic aorta (DTA) treated with TEVAR. Aortic arch and thoracoabdominal aortic aneurysm repairs are frequently required in this population. This study aims to analyze the short and mid-term outcomes after TEVAR in patients with SGA compared to those without. This will help to develop specific guidelines for the proper selection and treatment of patients with SGA and thoracic aortic pathologies. METHODS: The Society for Vascular Surgery Vascular Quality Initiative-Medicare-linked data was queried for patients who underwent TEVAR for DTA aneurysms and dissections with and without a history of SGA. Multivariable logistic regression was used to determine early post-operative outcomes. Kaplan-Meier curves were plotted to analyze mid-term survival trends, with the log-rank test used to compare outcomes between the groups within the specified time periods. Cox proportional hazards models were used to determine adjusted mid-term outcomes. Data was analyzed using Stata MP version 17.0. RESULTS: Out of 7,876 patients involved in the final analysis, 188 patients had a history of SGA, whereas 7,688 patients did not. Patients with SGA were overall younger (70.7 vs. 74.2 years, P < 0.01), but the groups had similar distributions of other baseline demographic characteristics. After adjusting for potential confounders, patients with SGA compared with those without had similar odds of 30-day mortality, postoperative stroke, spinal cord ischemia, myocardial infarction, congestive heart failure, and respiratory complications. There were no significant differences between the groups in overall mortality and reinterventions within the first year of follow-up. Three-year survival was not significantly different between the groups (73.7% vs. 63.1%, log-rank P = 0.11). After adjustment of confounders, Cox models demonstrated no significant differences between the groups in 3-year rates of overall mortality (aHR: 0.76, 95% CI: 0.51-1.12, P = 0.16); reinterventions (aHR: 1.09, 95% CI: 0.78-1.53, P = 0.61), and aortic rupture (aHR: 1.09, 95%CI: 0.45-2.65, P = 0.85). CONCLUSION: Despite their complex anatomical challenges, patients with SGA undergoing TEVAR have similar postoperative and mid-term outcomes compared to patients without SGA. Further studies are required to confirm these findings to support the use of TEVAR in patients with SGA.
引用
- Willie-Permor D, Veranyan N, Abdelkarim A, et al. Contemporary Outcomes of Thoracic Endovascular Aortic Repair in Patients with Syndromic Genetic Aortopathy: A Multi-Centre National Study. Ann Vasc Surg. 2026. PMID: 41643850. doi:10.1016/j.avsg.2026.01.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。